MedPath

Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma

Recruiting
Conditions
Multiple Myeloma
Registration Number
NCT06659276
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Brief Summary

The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
83
Inclusion Criteria
  • • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase

    • Patients who have signed the informed consent form
Exclusion Criteria
  • Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years

    • Age < 18 years
    • Women who are breastfeeding or pregnant
    • Patients with metal implants or devices that constitute an absolute contraindication for MRI
    • Patients with severe claustrophobia
    • Patients with bone pain that prevents prolonged maintenance of the supine position

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
positivity rate33 months

comparison per patient and per lesion between FDG PET CT and WB DWI

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Policlinico S.Orsola Malpighi

🇮🇹

Bologna, Italy

© Copyright 2025. All Rights Reserved by MedPath